Revance Therapeutics Inc
RVNC
7.37USD+0.28 (+3.95%)Market ClosedWatchlist
Market Summary
USD7.37+0.28
Market Closed3.95%
RVNC Stock Price
View Fullscreen
RVNC RSI Chart
RVNC Valuation
RVNC Price/Sales (Trailing)
RVNC Profitability
RVNC Fundamentals
RVNC Revenue
RVNC Earnings
Price Action
Last 7 days
1.8%
Last 30 days
-11.5%
Last 90 days
-52.4%
Trailing 12 Months
-66.6%
How does RVNC drawdown profile look like?
RVNC Financial Health
RVNC Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2023 | 156.6M | 186.4M | 214.2M | 0 |
| 2022 | 89.8M | 99.3M | 108.6M | 132.6M |
| 2021 | 28.6M | 47.1M | 63.0M | 77.8M |
| 2020 | 4.1M | 7.9M | 11.6M | 15.3M |
| 2019 | 4.3M | 4.8M | 5.1M | 413.0K |
| 2018 | 2.4M | 3.1M | 4.0M | 3.7M |
| 2017 | 1.2M | 1.2M | 963.0K | 1.7M |
| 2016 | 502.0K | 777.0K | 1.0M | 1.2M |
| 2015 | 252.0K | 226.0K | 219.0K | 219.0K |
| 2014 | 700.0K | 700.0K | 617.0K | 383.0K |
| 2013 | 266.8K | 383.5K | 500.3K | 617.0K |
| 2012 | 0 | 0 | 0 | 150.0K |
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for RVNC
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
| Sep 06, 2023 | moxie dwight | sold | -187,704 | 17.064 | -11,000 | svp, gc & secretary |
| Sep 05, 2023 | moxie dwight | sold | -424,920 | 17.8141 | -23,853 | svp, gc & secretary |
| Aug 11, 2023 | foley mark j | acquired | - | - | 122,143 | ceo |
| Aug 11, 2023 | sjuts dustin s | acquired | - | - | 22,620 | president |
| Aug 11, 2023 | moxie dwight | acquired | - | - | 19,346 | svp, gc & secretary |
| Aug 11, 2023 | schilke tobin | sold (taxes) | -212,076 | 18.91 | -11,215 | cfo |
| Aug 11, 2023 | sjuts dustin s | sold (taxes) | -168,318 | 18.91 | -8,901 | president |
| Aug 11, 2023 | schilke tobin | acquired | - | - | 22,620 | cfo |
| Aug 11, 2023 | moxie dwight | sold (taxes) | -181,385 | 18.91 | -9,592 | svp, gc & secretary |
| Aug 11, 2023 | foley mark j | sold (taxes) | -908,890 | 18.91 | -48,064 | ceo |
Which funds bought or sold RVNC recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
| Dec 06, 2023 | CITIGROUP INC | added | 27.17 | -415,089 | 564,610 | -% |
| Nov 30, 2023 | Neo Ivy Capital Management | sold off | -100 | -606,000 | - | -% |
| Nov 24, 2023 | DEUTSCHE BANK AG\ | added | 13.05 | -491,769 | 516,632 | -% |
| Nov 22, 2023 | Graham Capital Management, L.P. | reduced | -67.14 | -695,718 | 121,719 | -% |
| Nov 22, 2023 | Polar Capital Holdings Plc | reduced | -0.18 | -57,769,300 | 47,718,800 | 0.35% |
| Nov 22, 2023 | Public Sector Pension Investment Board | reduced | -30.71 | -4,410,020 | 2,018,720 | 0.01% |
| Nov 21, 2023 | COMERICA BANK | new | - | 39,617 | 39,617 | -% |
| Nov 21, 2023 | Walleye Trading LLC | added | 11,658 | 141,608 | 144,316 | -% |
| Nov 21, 2023 | Walleye Capital LLC | added | 168 | 627,460 | 3,507,430 | 0.01% |
| Nov 15, 2023 | MORGAN STANLEY | reduced | -5.87 | -9,285,050 | 6,907,180 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Revance Therapeutics Inc
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Oct 24, 2023 | teoxane sa | 7.4% | 6,550,800 | SC 13D/A | |
| Sep 01, 2023 | teoxane sa | 5.0% | 4,445,800 | SC 13D | |
| Feb 14, 2023 | antara capital lp | 6.4% | 5,239,600 | SC 13G | |
| Feb 14, 2023 | polar capital holdings plc | 5.9% | 4,848,633 | SC 13G | |
| Feb 14, 2023 | palo alto investors lp | 6.42% | 5,283,609 | SC 13G/A | |
| Feb 13, 2023 | capital world investors | 11.5% | 9,480,156 | SC 13G/A | |
| Feb 09, 2023 | gic private ltd | 6.68% | 5,492,965 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 5.47% | 4,496,316 | SC 13G/A | |
| Feb 03, 2023 | blackrock inc. | 8.6% | 7,072,681 | SC 13G/A | |
| Jan 27, 2023 | jpmorgan chase & co | 6.0% | 4,982,949 | SC 13G/A |
Recent SEC filings of Revance Therapeutics Inc
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Nov 14, 2023 | S-3ASR | S-3ASR | |
| Nov 08, 2023 | 8-K | Current Report | |
| Nov 08, 2023 | 10-Q | Quarterly Report | |
| Oct 24, 2023 | SC 13D/A | 13D - Major Acquisition | |
| Sep 19, 2023 | 8-K | Current Report | |
| Sep 07, 2023 | 4 | Insider Trading | |
| Sep 06, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 05, 2023 | 144 | Notice of Insider Sale Intent | |
| Sep 01, 2023 | SC 13D | 13D - Major Acquisition | |
| Aug 31, 2023 | 8-K | Current Report |
Peers (Alternatives to Revance Therapeutics Inc)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
HILS | 31.5B | - | 6.13% | 411799.31% | -3.7K | 218.4K | - | -102.45% |
MRNA | 30.6B | 10.7B | 12.59% | -56.51% | -8.83 | 2.87 | -53.67% | -129.46% |
ALNY | 21.3B | 1.7B | 0.38% | -28.56% | -41.84 | 12.38 | 79.37% | 56.87% |
BMRN | 17.5B | 2.3B | 8.71% | -10.95% | 119.09 | 7.58 | 15.05% | 75.21% |
INCY | 12.3B | 3.6B | 1.18% | -34.97% | 28.84 | 3.4 | 8.35% | -51.49% |
| MID-CAP | ||||||||
APLS | 7.4B | 272.9M | 33.62% | 24.68% | -12.26 | 27.23 | 141.38% | 4.43% |
BBIO | 5.7B | - | 10.65% | 240.88% | -9.69 | 48.33 | 54.84% | -12.96% |
ACAD | 3.4B | 631.9M | -9.53% | 43.40% | -23.12 | 5.44 | 23.54% | 31.53% |
AXSM | 3.3B | 223.4M | 14.00% | -9.85% | -16.45 | 14.86 | - | -26.24% |
ARWR | 2.6B | 240.7M | -11.63% | -24.14% | -12.52 | 10.67 | -1.03% | -16.59% |
| SMALL-CAP | ||||||||
CPRX | 1.5B | 348.4M | 12.92% | -15.71% | 24.33 | 4.33 | 81.69% | -7.29% |
NVAX | 661.3M | 1.0B | -18.09% | -67.84% | -1.2 | 0.63 | -43.15% | 58.48% |
INO | 100.5M | 6.4M | - | -79.35% | -0.61 | 15.6 | -44.11% | 50.48% |
IBIO | 37.6M | - | 385.71% | 119.35% | -0.58 | - | - | -29.23% |
CRBP | 23.7M | - | 40.31% | 4064.72% | -0.5 | - | - | -13.74% |
Revance Therapeutics Inc News
Latest updates
Financials for Revance Therapeutics Inc
Income Statement (Last 12 Months)
| Income Statement (Quarterly) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Revenue | -2.3% | 56,776,000 | 58,134,000 | 49,331,000 | 49,921,000 | 29,015,000 | 28,368,000 | 25,261,000 | 25,950,000 | 19,745,000 | 18,804,000 | 13,299,000 | 11,133,000 | 3,835,000 | 299,000 | 58,000 | 693,500 | 1,329,000 | 1,596,000 | 1,570,000 | 630,000 | 996,000 |
| Operating Expenses | 58.6% | 196,069,000 | 123,633,000 | 107,363,000 | 194,332,000 | 106,499,000 | 86,210,000 | 87,482,000 | 87,554,000 | 92,468,000 | 89,141,000 | 83,311,000 | 89,102,000 | 80,963,000 | 57,404,000 | 61,018,000 | 46,259,000 | 42,586,000 | 39,122,000 | 36,905,000 | 38,895,000 | 36,003,000 |
| S&GA Expenses | -10.7% | 69,094,000 | 77,384,000 | 66,011,000 | 65,237,000 | 65,775,000 | 47,847,000 | 45,075,000 | 46,436,000 | 52,782,000 | 50,598,000 | 49,005,000 | 52,833,000 | 48,183,000 | 29,606,000 | 21,224,000 | 18,766,000 | 16,739,000 | 13,596,000 | 12,910,000 | 13,358,000 | 14,155,000 |
| R&D Expenses | -42.7% | 13,060,000 | 22,807,000 | 23,177,000 | 19,541,000 | 26,103,000 | 24,913,000 | 30,729,000 | 29,468,000 | 30,095,000 | 29,441,000 | 27,251,000 | 29,768,000 | 29,130,000 | 27,103,000 | 39,794,000 | 27,493,000 | 25,847,000 | 25,526,000 | 23,995,000 | 25,537,000 | 21,848,000 |
| EBITDA Margin | - | - | - | - | - | - | -2.69 | -3.01 | -3.49 | -4.19 | - | -9.37 | -19.55 | -30.54 | -22.93 | -21.17 | -21.27 | -22.31 | -18.66 | - | - | - |
| Interest Expenses | 16.6% | 5,093,000 | 4,368,000 | 4,497,000 | 3,752,000 | 6,917,000 | 3,874,000 | 1,931,000 | 1,573,000 | 1,571,000 | 1,569,000 | 1,560,000 | 4,410,000 | 4,334,000 | 4,256,000 | 2,148,000 | - | - | - | - | - | - |
| Income Taxes | - | - | - | - | - | 700,000 | - | - | - | - | - | - | -2,720,000 | - | - | 100,000 | - | - | - | - | 3,000,000 | - |
| Earnings Before Taxes | - | - | - | - | - | - | - | - | - | -74,376,000 | - | - | - | -81,257,000 | - | - | - | - | - | - | - | - |
| EBT Margin | - | - | - | - | - | - | -3.00 | -3.31 | -3.82 | -4.63 | - | -10.27 | -21.21 | -32.27 | -25.01 | -22.11 | -21.80 | -22.86 | -19.11 | - | - | - |
| Net Income | -109.7% | -141,176,000 | -67,318,000 | -59,793,000 | -145,915,000 | -84,693,000 | -61,435,000 | -64,342,000 | -63,098,000 | -74,376,000 | -72,197,000 | -71,639,000 | -78,309,000 | -81,257,000 | -60,590,000 | -61,933,000 | -45,326,000 | -41,409,000 | -37,390,000 | -35,304,000 | -40,616,000 | -32,834,000 |
| Net Income Margin | -0.8% | -1.93 | -1.92 | -2.25 | -2.69 | -2.52 | -2.65 | -3.05 | -3.62 | -4.61 | -6.32 | -9.22 | -18.41 | -24.73 | -43.41 | -34.12 | - | - | - | - | - | - |
| Free Cashflow | -4.4% | -55,465,000 | -53,116,000 | -70,370,000 | -31,470,000 | -58,873,000 | -43,689,000 | -62,726,000 | -48,968,000 | -54,169,000 | -49,985,000 | -78,791,000 | -64,522,000 | -56,463,000 | -17,787,000 | -43,828,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Assets | -10.9% | 532 | 598 | 548 | 582 | 712 | 562 | 640 | 531 | 582 | 641 | 676 | 720 | 712 | 576 | 593 | 340 | 266 | 296 | 324 | 226 | 233 |
| Current Assets | 2.5% | 389 | 379 | 323 | 375 | 416 | 261 | 285 | 246 | 294 | 355 | 406 | 450 | 450 | 503 | 518 | 297 | 221 | 250 | 277 | 208 | 216 |
| Cash Equivalents | 32.2% | 187 | 141 | 137 | 109 | 104 | 75.00 | 204 | 116 | 132 | 171 | 253 | 337 | 341 | 365 | 287 | 172 | 60.00 | 91.00 | 66.00 | 74.00 | 46.00 |
| Inventory | 34.2% | 46.00 | 34.00 | 28.00 | 18.00 | 17.00 | 14.00 | 11.00 | 10.00 | 10.00 | 5.00 | 6.00 | 6.00 | 4.00 | 1.00 | - | - | - | - | - | - | - |
| Net PPE | 35.4% | 17.00 | 13.00 | 14.00 | 14.00 | 23.00 | 23.00 | 23.00 | 25.00 | 22.00 | 21.00 | 21.00 | 17.00 | 15.00 | 14.00 | 14.00 | 15.00 | 15.00 | 15.00 | 15.00 | 14.00 | 13.00 |
| Goodwill | -100.0% | - | 77.00 | 77.00 | 77.00 | 147 | 147 | 147 | 147 | 147 | 147 | 147 | 147 | 145 | - | - | - | - | - | - | - | - |
| Liabilities | 11.9% | 639 | 571 | 574 | 569 | 566 | 565 | 614 | 463 | 462 | 455 | 432 | 346 | 339 | 320 | 285 | 115 | 115 | 107 | 103 | 81.00 | 51.00 |
| Current Liabilities | 10.9% | 82.00 | 74.00 | 78.00 | 76.00 | 75.00 | 77.00 | 71.00 | 67.00 | 66.00 | 58.00 | 51.00 | 61.00 | 64.00 | 48.00 | 42.00 | 41.00 | 34.00 | 45.00 | 34.00 | 32.00 | 32.00 |
| Long Term Debt | 12.6% | 428 | 380 | 380 | 379 | 379 | 378 | 378 | 281 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Shareholder's Equity | -496.5% | -106 | 27.00 | - | 13.00 | 146 | - | 26.00 | 68.00 | 120 | 186 | 244 | 374 | 373 | 256 | 308 | 225 | 151 | 189 | 221 | 146 | 182 |
| Retained Earnings | -6.3% | -2,000 | -1,881 | -1,814 | -1,754 | -1,608 | -1,500 | -1,500 | -1,397 | -1,334 | -1,300 | -1,200 | -1,126 | -1,050 | -966 | -906 | -844 | -798 | -757 | -720 | -684 | -644 |
| Additional Paid-In Capital | 0.4% | 1,916 | 1,908 | 1,788 | 1,767 | 1,755 | 1,521 | 1,488 | 1,466 | 1,455 | 1,447 | 1,432 | 1,501 | 1,421 | 1,222 | 1,214 | 1,070 | 950 | 946 | 941 | 830 | 826 |
| Shares Outstanding | -0.2% | 88.00 | 88.00 | 84.00 | 82.00 | 82.00 | 73.00 | 72.00 | 72.00 | 72.00 | 72.00 | 71.00 | 69.00 | 67.00 | 57.00 | 57.00 | 52.00 | 44.00 | 44.00 | 44.00 | 36.00 | 37.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Quarterly) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Cashflow From Operations | 4.5% | -50,962 | -53,382 | -69,500 | -30,182 | -57,871 | -44,225 | -61,270 | -44,611 | -53,167 | -49,005 | -74,755 | -62,314 | -55,686 | -17,213 | -43,289 | -33,508 | -31,949 | -29,290 | -11,414 | -31,141 | -25,404 |
| Share Based Compensation | -34.1% | 10,287 | 15,599 | 13,082 | 10,727 | 17,987 | 9,263 | 14,363 | 10,921 | 10,538 | 11,368 | 10,607 | 11,879 | 10,677 | 7,353 | 6,544 | 5,040 | 4,303 | 4,420 | 4,159 | 3,851 | 4,092 |
| Cashflow From Investing | 230.5% | 51,586 | -39,532 | 95,316 | 40,960 | -118,445 | -105,881 | 44,568 | 27,641 | 16,807 | -35,693 | -38,420 | -8,691 | 32,496 | 93,895 | -105,569 | 30,919 | 918 | 54,012 | -103,441 | 59,101 | 30,359 |
| Cashflow From Financing | -61.6% | 37,460 | 97,471 | 3,265 | -6,173 | 211,389 | 21,165 | 105,313 | 405 | -2,492 | 2,912 | 29,044 | 67,324 | -687 | 500 | 264,347 | 114,827 | -81.00 | 43.00 | 106,868 | 164 | 895 |
RVNC Income Statement
2023-09-30Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
| Revenue: | ||||
| Total revenue | $ 56,776 | $ 29,015 | $ 164,241 | $ 82,644 |
| Operating expenses: | ||||
| Selling, general and administrative | 69,094 | 65,775 | 212,489 | 158,697 |
| Research and development | 13,060 | 26,103 | 59,044 | 81,745 |
| Goodwill impairment | 77,175 | 0 | 77,175 | 0 |
| Intangible asset impairment | 16,007 | 0 | 16,007 | 0 |
| Depreciation and amortization | 1,320 | 3,885 | 5,459 | 11,597 |
| Total operating expenses | 196,069 | 106,499 | 427,065 | 280,191 |
| Loss from operations | (139,293) | (77,484) | (262,824) | (197,547) |
| Interest income | 3,733 | 1,165 | 9,851 | 1,860 |
| Interest expense | (5,093) | (6,917) | (13,958) | (12,722) |
| Other expense, net | (223) | (757) | (1,056) | (1,361) |
| Loss before income taxes | (140,876) | (83,993) | (267,987) | (209,770) |
| Income tax provision | (300) | (700) | (300) | (700) |
| Net loss | (141,176) | (84,693) | (268,287) | (210,470) |
| Unrealized gain (loss) | 48 | (74) | 361 | (442) |
| Comprehensive loss | (141,128) | (84,767) | (267,926) | (210,912) |
| Basic net loss | (141,176) | (84,693) | (268,287) | (210,470) |
| Diluted net loss | $ (141,176) | $ (84,693) | $ (268,287) | $ (210,470) |
| Basic net loss (in dollars per share) | $ (1.63) | $ (1.17) | $ (3.20) | $ (3.00) |
| Diluted net loss (in dollars per share) | $ (1.63) | $ (1.17) | $ (3.20) | $ (3.00) |
| Basic weighted-average number of shares used in computing net loss per share (in shares) | 86,613,425 | 72,208,285 | 83,816,577 | 70,215,148 |
| Diluted weighted-average number of shares used in computing net loss per share (in shares) | 86,613,425 | 72,208,285 | 83,816,577 | 70,215,148 |
| Product revenue | ||||
| Revenue: | ||||
| Total revenue | $ 54,109 | $ 26,081 | $ 154,160 | $ 72,401 |
| Operating expenses: | ||||
| Cost of product revenue /service revenue (exclusive of amortization of intangible assets) | 16,821 | 8,681 | 46,915 | 24,130 |
| Service revenue | ||||
| Revenue: | ||||
| Total revenue | 2,664 | 1,964 | 9,942 | 4,046 |
| Operating expenses: | ||||
| Cost of product revenue /service revenue (exclusive of amortization of intangible assets) | 2,592 | 2,055 | 9,976 | 4,022 |
| Collaboration revenue | ||||
| Revenue: | ||||
| Total revenue | $ 3 | $ 970 | $ 139 | $ 6,197 |
RVNC Balance Sheet
2023-09-30Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| CURRENT ASSETS | ||
| Cash and cash equivalents | $ 179,319 | $ 108,965 |
| Restricted cash, current | 275 | 0 |
| Short-term investments | 120,926 | 231,742 |
| Accounts receivable, net | 25,414 | 11,339 |
| Inventories | 46,214 | 18,325 |
| Prepaid expenses and other current assets | 16,371 | 4,356 |
| Total current assets | 388,519 | 374,727 |
| Property and equipment, net | 17,179 | 13,799 |
| Goodwill | 0 | 77,175 |
| Intangible assets, net | 10,507 | 35,344 |
| Operating lease right-of-use assets | 54,810 | 39,223 |
| Finance lease right-of-use asset | 23,209 | 6,393 |
| Restricted cash, non-current | 7,145 | 6,052 |
| Finance lease prepaid expense | 30,883 | 27,500 |
| Other non-current assets | 235 | 1,687 |
| TOTAL ASSETS | 532,487 | 581,900 |
| CURRENT LIABILITIES | ||
| Accounts payable | 4,775 | 4,546 |
| Accruals and other current liabilities | 53,493 | 59,357 |
| Deferred revenue, current | 5,371 | 6,867 |
| Finance lease liability, current | 8,610 | 669 |
| Operating lease liabilities, current | 8,659 | 4,243 |
| Debt, current | 1,250 | 0 |
| Total current liabilities | 82,158 | 75,682 |
| Debt, non-current | 427,101 | 379,374 |
| Deferred revenue, non-current | 84,315 | 78,577 |
| Operating lease liabilities, non-current | 42,279 | 34,182 |
| Other non-current liabilities | 2,835 | 1,485 |
| TOTAL LIABILITIES | 638,688 | 569,300 |
| Commitments and Contingencies (Note 12) | ||
| STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Preferred stock, par value $0.001 per share — 5,000,000 shares authorized, and no shares issued and outstanding as of September 30, 2023 and December 31, 2022 | 0 | 0 |
| Common stock, par value $0.001 per share — 190,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 87,813,315 and 82,385,810 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively | 88 | 82 |
| Additional paid-in capital | 1,916,385 | 1,767,266 |
| Accumulated other comprehensive loss | (13) | (374) |
| Accumulated deficit | (2,022,661) | (1,754,374) |
| TOTAL STOCKHOLDERS’ EQUITY (DEFICIT) | (106,201) | 12,600 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | $ 532,487 | $ 581,900 |
| CEO | Mr. Mark J. Foley |
|---|---|
| WEBSITE | www.revance.com |
| EMPLOYEES | 534 |